Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
Rennes University Hospital
50 participants
Mar 22, 2025
INTERVENTIONAL
Conditions
Summary
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Eligibility
Inclusion Criteria7
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
- Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
- Beneficiary of a social security scheme
Exclusion Criteria3
- Isolated extramedullary involvement at inclusion
- Patient of childbearing age without effective contraception.
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Interventions
Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06649253